Xanthine Oxidase Inhibitors

Xanthine Oxidase Inhibitors
Accession Number
DBCAT002773  (DBCAT002774, DBCAT002775, DBCAT003814)

An xanthine oxidase inhibitor is any substance that inhibits the activity of xanthine oxidase, an enzyme involved in purine metabolism. In humans, inhibition of xanthine oxidase reduces the production of uric acid, and several medications that inhibit xanthine oxidase are indicated for treatment of hyperuricemia and related medical conditions including gout.

DrugDrug Description
AllopurinolA xanthine oxidase inhibitor used to reduce urinary and serum uric acid concentrations in patients with gout, recurrent calcium oxalate calculi, and various malignancies.
FebuxostatA xanthine oxidase inhibitor used for the management of chronic hyperuricemia in patients with gout.
OxypurinolIntended for the treatment of congestive heart failure and hyperuricemia.
Drugs & Drug Targets
AllopurinolXanthine dehydrogenase/oxidasetarget
AllopurinolSolute carrier family 22 member 8transporter
AllopurinolSolute carrier family 22 member 7transporter
AllopurinolAldehyde oxidaseenzyme
AllopurinolXanthine dehydrogenase/oxidaseenzyme
AllopurinolATP-binding cassette sub-family G member 2transporter
AllopurinolSolute carrier family 22 member 2transporter
FebuxostatXanthine dehydrogenase/oxidasetarget
OxypurinolXanthine dehydrogenase/oxidasetarget